[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQc4Nvggq-c-uZ6oU4KNJ5i_EYTWwl8ZNgn3Yc8dtr9g":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":83,"rows":90},"Instituto do Cancer do Estado de São Paulo",[4],88,false,20,5,11347,21,48,[14,17,20,22,24,27,29,31],{"name":15,"count":16},"Breast Cancer",8,{"name":18,"count":19},"Prostate Cancer",6,{"name":21,"count":9},"Gastric Cancer",{"name":23,"count":9},"Rectal Cancer",{"name":25,"count":26},"Head and Neck Cancer",3,{"name":28,"count":26},"Postoperative Nausea",{"name":30,"count":26},"Cancer",{"name":32,"count":26},"Postoperative Nausea and Vomiting",[34,39,44,49,54,59,63,68,73,78],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06638931","Agnostic Therapy in Rare Solid Tumors","2026-07","Nivolumab",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07316686","Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma","2026-09","Docetaxel 50mg\u002Fm2",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05622136","Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma","2026-11-15","Regorafenib Oral Product",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06640283","Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes","2026-12","Pembrolizumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT03825861","Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer","2026-12-30","FOLFIRINOX",{"nctId":60,"briefTitle":61,"date":62,"intervention":53},"NCT07376317","Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)","2027-01-30",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06887621","Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery","2027-03-29","Encapsulated amisulpride 50 mg",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05959720","Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil","2028-06","Prednisone",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06034561","Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia","2028-08","Bortezomib",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06982274","Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia","2028-11","Realgar-Indigo Naturalis Formulation",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,131,206,228,248,271,289,311,334,358,376,394,442,460,478,496,514,532,550,568,586,604,637,664,682,700,727,745,763,790,808,833,857,882,907,940,958,984,1002,1020,1038,1065,1091,1118,1136,1161,1186,1212,1238,1262,1288,1306,1332,1350,1375,1393,1416,1441,1467,1485,1509,1537,1555],{"intervention":53,"totalTrials":92,"cells":93},2,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":125,"PHASE4":127,"NA":129},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":92,"soonestReadout":52},[101,112],{"nctId":60,"briefTitle":61,"status":102,"phases":103,"primaryCompletion":62,"completion":62,"start":104,"enrollment":105,"conditions":106,"interventions":111},"ACTIVE_NOT_RECRUITING",[86],"2021-12-10",29,[107,108,109,110],"Melanoma Metastatic","Melanoma Recurrent","Cutaneous Melanoma","Stage IV Melanoma",[53],{"nctId":50,"briefTitle":51,"status":113,"phases":114,"primaryCompletion":52,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":124},"RECRUITING",[86],"2027-01","2025-03-14",150,[119,120,121,122,123],"HPV-Related Carcinoma","Uterine Cervical Cancer","Anal Canal Cancer","HPV-Related Anal Squamous Cell Carcinoma","HPV-Related Cervical Carcinoma",[53],{"trials":126,"activeCount":96},[],{"trials":128,"activeCount":96},[],{"trials":130,"activeCount":96},[],{"intervention":38,"totalTrials":92,"cells":132},{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":200,"PHASE4":202,"NA":204},{"trials":134,"activeCount":96},[],{"trials":136,"activeCount":96},[],{"trials":138,"activeCount":199,"soonestReadout":37},[139,187],{"nctId":35,"briefTitle":36,"status":113,"phases":140,"primaryCompletion":37,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":186},[86],"2028-05","2024-07-16",28,[145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185],"Urachal Cancer","Parathyroid Carcinoma","Fibrolamellar Carcinoma","Angiosarcoma","Secretory Carcinoma of Breast","Anal Neoplasms","Metaplastic Breast Carcinoma","Translocation Renal Cell Carcinoma","Carcinosarcoma","Small Intestine Neoplasms","Cholangiocarcinoma","Sertoli-Leydig Cell Tumor","Adenoid Cystic Carcinoma","Mesothelioma","Neuroblastoma","Adrenal Gland Neoplasms","Penile Neoplasms","Apocrine Carcinoma","Fibrosarcoma","Cancer of Unknown Primary","Hemangioblastoma","Thyroid Neoplasms","Hepatoblastoma","Fallopian Tube Neoplasms","Leiomyosarcoma","Vaginal Neoplasms","Neurofibrosarcoma","Gallbladder Neoplasms","Osteosarcoma","Biliary Tract Neoplasms","Clear Cell Endometrial Cancer","Yolk Sac Tumor","Vulvar Neoplasms","Kaposi Sarcoma","Ovarian Epithelial Cancer","Soft Tissue Sarcoma","Urethral Neoplasms","Granulosa Cell Tumor","Primitive Neuroectodermal Tumor","Neuroendocrine Tumors","Trophoblastic Tumor",[38],{"nctId":188,"briefTitle":189,"status":190,"phases":191,"primaryCompletion":192,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":198},"NCT03834233","Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma","UNKNOWN",[86],"2019-12-01","2022-12-01","2019-09-05",24,[197],"Advanced Cutaneous Squamous Cell Carcinoma",[38],1,{"trials":201,"activeCount":96},[],{"trials":203,"activeCount":96},[],{"trials":205,"activeCount":96},[],{"intervention":48,"totalTrials":199,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":222,"PHASE4":224,"NA":226},{"trials":209,"activeCount":96},[],{"trials":211,"activeCount":96},[],{"trials":213,"activeCount":199,"soonestReadout":47},[214],{"nctId":45,"briefTitle":46,"status":102,"phases":215,"primaryCompletion":47,"completion":216,"start":217,"enrollment":143,"conditions":218,"interventions":221},[86],"2026-12-15","2023-09-10",[219,220],"Liver Cancer","Hepatocellular Carcinoma",[48],{"trials":223,"activeCount":96},[],{"trials":225,"activeCount":96},[],{"trials":227,"activeCount":96},[],{"intervention":58,"totalTrials":199,"cells":229},{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":242,"PHASE4":244,"NA":246},{"trials":231,"activeCount":96},[],{"trials":233,"activeCount":96},[],{"trials":235,"activeCount":199,"soonestReadout":57},[236],{"nctId":55,"briefTitle":56,"status":113,"phases":237,"primaryCompletion":57,"completion":57,"start":238,"enrollment":239,"conditions":240,"interventions":241},[86],"2017-02-23",27,[21],[58],{"trials":243,"activeCount":96},[],{"trials":245,"activeCount":96},[],{"trials":247,"activeCount":96},[],{"intervention":67,"totalTrials":199,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":265,"PHASE4":267,"NA":269},{"trials":251,"activeCount":96},[],{"trials":253,"activeCount":96},[],{"trials":255,"activeCount":199,"soonestReadout":66},[256],{"nctId":64,"briefTitle":65,"status":113,"phases":257,"primaryCompletion":66,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":263},[86],"2027-03-31","2025-04-10",276,[262],"Post Operative Nausea and Vomiting (PONV)",[67,264],"Encapsulated placebo",{"trials":266,"activeCount":96},[],{"trials":268,"activeCount":96},[],{"trials":270,"activeCount":96},[],{"intervention":264,"totalTrials":199,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":283,"PHASE4":285,"NA":287},{"trials":274,"activeCount":96},[],{"trials":276,"activeCount":96},[],{"trials":278,"activeCount":199,"soonestReadout":66},[279],{"nctId":64,"briefTitle":65,"status":113,"phases":280,"primaryCompletion":66,"completion":258,"start":259,"enrollment":260,"conditions":281,"interventions":282},[86],[262],[67,264],{"trials":284,"activeCount":96},[],{"trials":286,"activeCount":96},[],{"trials":288,"activeCount":96},[],{"intervention":82,"totalTrials":199,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":305,"PHASE4":307,"NA":309},{"trials":292,"activeCount":96},[],{"trials":294,"activeCount":96},[],{"trials":296,"activeCount":199,"soonestReadout":81},[297],{"nctId":79,"briefTitle":80,"status":113,"phases":298,"primaryCompletion":81,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":304},[86],"2029-11","2023-10-20",115,[303],"Acute Promyelocytic Leukemia (APL)",[82],{"trials":306,"activeCount":96},[],{"trials":308,"activeCount":96},[],{"trials":310,"activeCount":96},[],{"intervention":77,"totalTrials":199,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":328,"PHASE4":330,"NA":332},{"trials":314,"activeCount":96},[],{"trials":316,"activeCount":96},[],{"trials":318,"activeCount":199,"soonestReadout":76},[319],{"nctId":74,"briefTitle":75,"status":113,"phases":320,"primaryCompletion":76,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":327},[86],"2029-08","2024-04-01",50,[325,326],"Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission",[77],{"trials":329,"activeCount":96},[],{"trials":331,"activeCount":96},[],{"trials":333,"activeCount":96},[],{"intervention":43,"totalTrials":199,"cells":335},{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":350,"PHASE3":352,"PHASE4":354,"NA":356},{"trials":337,"activeCount":96},[],{"trials":339,"activeCount":199,"soonestReadout":42},[340],{"nctId":40,"briefTitle":41,"status":341,"phases":342,"primaryCompletion":42,"completion":52,"start":343,"enrollment":344,"conditions":345,"interventions":347},"NOT_YET_RECRUITING",[85],"2026-06",18,[346],"Prostate Cancer (Adenocarcinoma)",[43,348,349],"Docetaxel 60mg\u002Fm2","Docetaxel 75 mg\u002Fm²",{"trials":351,"activeCount":96},[],{"trials":353,"activeCount":96},[],{"trials":355,"activeCount":96},[],{"trials":357,"activeCount":96},[],{"intervention":348,"totalTrials":199,"cells":359},{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":374},{"trials":361,"activeCount":96},[],{"trials":363,"activeCount":199,"soonestReadout":42},[364],{"nctId":40,"briefTitle":41,"status":341,"phases":365,"primaryCompletion":42,"completion":52,"start":343,"enrollment":344,"conditions":366,"interventions":367},[85],[346],[43,348,349],{"trials":369,"activeCount":96},[],{"trials":371,"activeCount":96},[],{"trials":373,"activeCount":96},[],{"trials":375,"activeCount":96},[],{"intervention":349,"totalTrials":199,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":379,"activeCount":96},[],{"trials":381,"activeCount":199,"soonestReadout":42},[382],{"nctId":40,"briefTitle":41,"status":341,"phases":383,"primaryCompletion":42,"completion":52,"start":343,"enrollment":344,"conditions":384,"interventions":385},[85],[346],[43,348,349],{"trials":387,"activeCount":96},[],{"trials":389,"activeCount":96},[],{"trials":391,"activeCount":96},[],{"trials":393,"activeCount":96},[],{"intervention":72,"totalTrials":92,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":416,"PHASE4":418,"NA":420},{"trials":397,"activeCount":96},[],{"trials":399,"activeCount":96},[],{"trials":401,"activeCount":96},[402],{"nctId":403,"briefTitle":404,"status":405,"phases":406,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":412},"NCT02789878","Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer","COMPLETED",[86],"2022-04-30","2022-08-01","2019-01-24",64,[18],[413,72,414,415],"Goserelin","Abiraterone","Apalutamide",{"trials":417,"activeCount":96},[],{"trials":419,"activeCount":96},[],{"trials":421,"activeCount":199,"soonestReadout":71},[422],{"nctId":69,"briefTitle":70,"status":113,"phases":423,"primaryCompletion":71,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":432},[],"2030-06","2023-09-05",180,[428,429,430,431],"Acute Lymphoid Leukemia","Minimal Residual Disease","Gene Abnormality","Chemotherapeutic Toxicity",[72,433,434,435,436,437,438,439,440,441],"Vincristin","Daunorubicin","Peg-asparaginase","Intrathecal Suspension","Cyclophosphamide","Cytarabine","Mercaptopurine","Methotrexate","Doxorubicin",{"intervention":433,"totalTrials":199,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":445,"activeCount":96},[],{"trials":447,"activeCount":96},[],{"trials":449,"activeCount":96},[],{"trials":451,"activeCount":96},[],{"trials":453,"activeCount":96},[],{"trials":455,"activeCount":199,"soonestReadout":71},[456],{"nctId":69,"briefTitle":70,"status":113,"phases":457,"primaryCompletion":71,"completion":424,"start":425,"enrollment":426,"conditions":458,"interventions":459},[],[428,429,430,431],[72,433,434,435,436,437,438,439,440,441],{"intervention":434,"totalTrials":199,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":470,"NA":472},{"trials":463,"activeCount":96},[],{"trials":465,"activeCount":96},[],{"trials":467,"activeCount":96},[],{"trials":469,"activeCount":96},[],{"trials":471,"activeCount":96},[],{"trials":473,"activeCount":199,"soonestReadout":71},[474],{"nctId":69,"briefTitle":70,"status":113,"phases":475,"primaryCompletion":71,"completion":424,"start":425,"enrollment":426,"conditions":476,"interventions":477},[],[428,429,430,431],[72,433,434,435,436,437,438,439,440,441],{"intervention":435,"totalTrials":199,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":490},{"trials":481,"activeCount":96},[],{"trials":483,"activeCount":96},[],{"trials":485,"activeCount":96},[],{"trials":487,"activeCount":96},[],{"trials":489,"activeCount":96},[],{"trials":491,"activeCount":199,"soonestReadout":71},[492],{"nctId":69,"briefTitle":70,"status":113,"phases":493,"primaryCompletion":71,"completion":424,"start":425,"enrollment":426,"conditions":494,"interventions":495},[],[428,429,430,431],[72,433,434,435,436,437,438,439,440,441],{"intervention":436,"totalTrials":199,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":508},{"trials":499,"activeCount":96},[],{"trials":501,"activeCount":96},[],{"trials":503,"activeCount":96},[],{"trials":505,"activeCount":96},[],{"trials":507,"activeCount":96},[],{"trials":509,"activeCount":199,"soonestReadout":71},[510],{"nctId":69,"briefTitle":70,"status":113,"phases":511,"primaryCompletion":71,"completion":424,"start":425,"enrollment":426,"conditions":512,"interventions":513},[],[428,429,430,431],[72,433,434,435,436,437,438,439,440,441],{"intervention":437,"totalTrials":199,"cells":515},{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":526},{"trials":517,"activeCount":96},[],{"trials":519,"activeCount":96},[],{"trials":521,"activeCount":96},[],{"trials":523,"activeCount":96},[],{"trials":525,"activeCount":96},[],{"trials":527,"activeCount":199,"soonestReadout":71},[528],{"nctId":69,"briefTitle":70,"status":113,"phases":529,"primaryCompletion":71,"completion":424,"start":425,"enrollment":426,"conditions":530,"interventions":531},[],[428,429,430,431],[72,433,434,435,436,437,438,439,440,441],{"intervention":438,"totalTrials":199,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":544},{"trials":535,"activeCount":96},[],{"trials":537,"activeCount":96},[],{"trials":539,"activeCount":96},[],{"trials":541,"activeCount":96},[],{"trials":543,"activeCount":96},[],{"trials":545,"activeCount":199,"soonestReadout":71},[546],{"nctId":69,"briefTitle":70,"status":113,"phases":547,"primaryCompletion":71,"completion":424,"start":425,"enrollment":426,"conditions":548,"interventions":549},[],[428,429,430,431],[72,433,434,435,436,437,438,439,440,441],{"intervention":439,"totalTrials":199,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":553,"activeCount":96},[],{"trials":555,"activeCount":96},[],{"trials":557,"activeCount":96},[],{"trials":559,"activeCount":96},[],{"trials":561,"activeCount":96},[],{"trials":563,"activeCount":199,"soonestReadout":71},[564],{"nctId":69,"briefTitle":70,"status":113,"phases":565,"primaryCompletion":71,"completion":424,"start":425,"enrollment":426,"conditions":566,"interventions":567},[],[428,429,430,431],[72,433,434,435,436,437,438,439,440,441],{"intervention":440,"totalTrials":199,"cells":569},{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":578,"NA":580},{"trials":571,"activeCount":96},[],{"trials":573,"activeCount":96},[],{"trials":575,"activeCount":96},[],{"trials":577,"activeCount":96},[],{"trials":579,"activeCount":96},[],{"trials":581,"activeCount":199,"soonestReadout":71},[582],{"nctId":69,"briefTitle":70,"status":113,"phases":583,"primaryCompletion":71,"completion":424,"start":425,"enrollment":426,"conditions":584,"interventions":585},[],[428,429,430,431],[72,433,434,435,436,437,438,439,440,441],{"intervention":441,"totalTrials":199,"cells":587},{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":596,"NA":598},{"trials":589,"activeCount":96},[],{"trials":591,"activeCount":96},[],{"trials":593,"activeCount":96},[],{"trials":595,"activeCount":96},[],{"trials":597,"activeCount":96},[],{"trials":599,"activeCount":199,"soonestReadout":71},[600],{"nctId":69,"briefTitle":70,"status":113,"phases":601,"primaryCompletion":71,"completion":424,"start":425,"enrollment":426,"conditions":602,"interventions":603},[],[428,429,430,431],[72,433,434,435,436,437,438,439,440,441],{"intervention":605,"totalTrials":92,"cells":606},"Aprepitant",{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":613,"PHASE4":615,"NA":635},{"trials":608,"activeCount":96},[],{"trials":610,"activeCount":96},[],{"trials":612,"activeCount":96},[],{"trials":614,"activeCount":96},[],{"trials":616,"activeCount":96},[617,627],{"nctId":618,"briefTitle":619,"status":190,"phases":620,"primaryCompletion":621,"completion":621,"start":622,"enrollment":623,"conditions":624,"interventions":625},"NCT02431286","Palonosetron Associated to Aprepitant in Prophylaxis of PONV",[88],"2015-12","2014-10",90,[32],[605,626],"Dexamethasone",{"nctId":628,"briefTitle":629,"status":405,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":623,"conditions":633,"interventions":634},"NCT02357693","Neurokinin Receptor Antagonist Associated to Ondansetron in PONV",[88],"2015-08","2015-02",[32],[605],{"trials":636,"activeCount":96},[],{"intervention":638,"totalTrials":199,"cells":639},"Ketorolac",{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":648,"NA":662},{"trials":641,"activeCount":96},[],{"trials":643,"activeCount":96},[],{"trials":645,"activeCount":96},[],{"trials":647,"activeCount":96},[],{"trials":649,"activeCount":96},[650],{"nctId":651,"briefTitle":652,"status":405,"phases":653,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":659},"NCT02508857","Magnesium Sulfate Improves Postoperative Analgesia in Laparoscopic Gynecologic Surgeries",[88],"2014-01","2010-01",60,[658],"Pain, Postoperative",[638,660,661],"Magnesium","Saline solution",{"trials":663,"activeCount":96},[],{"intervention":660,"totalTrials":199,"cells":665},{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":674,"NA":680},{"trials":667,"activeCount":96},[],{"trials":669,"activeCount":96},[],{"trials":671,"activeCount":96},[],{"trials":673,"activeCount":96},[],{"trials":675,"activeCount":96},[676],{"nctId":651,"briefTitle":652,"status":405,"phases":677,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":678,"interventions":679},[88],[658],[638,660,661],{"trials":681,"activeCount":96},[],{"intervention":661,"totalTrials":199,"cells":683},{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":690,"PHASE4":692,"NA":698},{"trials":685,"activeCount":96},[],{"trials":687,"activeCount":96},[],{"trials":689,"activeCount":96},[],{"trials":691,"activeCount":96},[],{"trials":693,"activeCount":96},[694],{"nctId":651,"briefTitle":652,"status":405,"phases":695,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":696,"interventions":697},[88],[658],[638,660,661],{"trials":699,"activeCount":96},[],{"intervention":701,"totalTrials":199,"cells":702},"Local steroid - triamcinolone acetonide",{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":711,"NA":725},{"trials":704,"activeCount":96},[],{"trials":706,"activeCount":96},[],{"trials":708,"activeCount":96},[],{"trials":710,"activeCount":96},[],{"trials":712,"activeCount":96},[713],{"nctId":714,"briefTitle":715,"status":190,"phases":716,"primaryCompletion":717,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":723},"NCT04498260","Intralesional Steroid Injection Versus Oral Prednisolone in Prevention of Esophageal Stricture",[88],"2021-03-21","2021-06-21","2019-01-21",30,[722],"Esophageal Stenosis",[701,724],"Oral steroid - predonisolone",{"trials":726,"activeCount":96},[],{"intervention":724,"totalTrials":199,"cells":728},{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":735,"PHASE4":737,"NA":743},{"trials":730,"activeCount":96},[],{"trials":732,"activeCount":96},[],{"trials":734,"activeCount":96},[],{"trials":736,"activeCount":96},[],{"trials":738,"activeCount":96},[739],{"nctId":714,"briefTitle":715,"status":190,"phases":740,"primaryCompletion":717,"completion":718,"start":719,"enrollment":720,"conditions":741,"interventions":742},[88],[722],[701,724],{"trials":744,"activeCount":96},[],{"intervention":626,"totalTrials":199,"cells":746},{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":755,"NA":761},{"trials":748,"activeCount":96},[],{"trials":750,"activeCount":96},[],{"trials":752,"activeCount":96},[],{"trials":754,"activeCount":96},[],{"trials":756,"activeCount":96},[757],{"nctId":618,"briefTitle":619,"status":190,"phases":758,"primaryCompletion":621,"completion":621,"start":622,"enrollment":623,"conditions":759,"interventions":760},[88],[32],[605,626],{"trials":762,"activeCount":96},[],{"intervention":764,"totalTrials":199,"cells":765},"Vasopressin",{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":772,"PHASE4":786,"NA":788},{"trials":767,"activeCount":96},[],{"trials":769,"activeCount":96},[],{"trials":771,"activeCount":96},[],{"trials":773,"activeCount":96},[774],{"nctId":775,"briefTitle":776,"status":405,"phases":777,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":784},"NCT01718613","Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients",[87],"2014-03","2018-05","2012-11",250,[783],"Septic Shock",[764,785],"Norepinephrine",{"trials":787,"activeCount":96},[],{"trials":789,"activeCount":96},[],{"intervention":785,"totalTrials":199,"cells":791},{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":798,"PHASE4":804,"NA":806},{"trials":793,"activeCount":96},[],{"trials":795,"activeCount":96},[],{"trials":797,"activeCount":96},[],{"trials":799,"activeCount":96},[800],{"nctId":775,"briefTitle":776,"status":405,"phases":801,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":802,"interventions":803},[87],[783],[764,785],{"trials":805,"activeCount":96},[],{"trials":807,"activeCount":96},[],{"intervention":809,"totalTrials":199,"cells":810},"Tranexamic acid",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":829,"NA":831},{"trials":812,"activeCount":96},[],{"trials":814,"activeCount":96},[],{"trials":816,"activeCount":96},[],{"trials":818,"activeCount":96},[819],{"nctId":820,"briefTitle":821,"status":190,"phases":822,"primaryCompletion":823,"completion":824,"start":825,"enrollment":826,"conditions":827,"interventions":828},"NCT05816668","Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy",[87],"2024-04","2024-09","2023-04",122,[18],[809],{"trials":830,"activeCount":96},[],{"trials":832,"activeCount":96},[],{"intervention":834,"totalTrials":199,"cells":835},"Olanzapine",{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":853,"NA":855},{"trials":837,"activeCount":96},[],{"trials":839,"activeCount":96},[],{"trials":841,"activeCount":96},[],{"trials":843,"activeCount":96},[844],{"nctId":845,"briefTitle":846,"status":405,"phases":847,"primaryCompletion":848,"completion":848,"start":849,"enrollment":850,"conditions":851,"interventions":852},"NCT03631004","Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients",[86,87],"2021-02-10","2018-10-01",100,[28,32],[834],{"trials":854,"activeCount":96},[],{"trials":856,"activeCount":96},[],{"intervention":858,"totalTrials":199,"cells":859},"Red blood cell transfusion",{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":866,"PHASE4":878,"NA":880},{"trials":861,"activeCount":96},[],{"trials":863,"activeCount":96},[],{"trials":865,"activeCount":96},[],{"trials":867,"activeCount":96},[868],{"nctId":869,"briefTitle":870,"status":190,"phases":871,"primaryCompletion":872,"completion":872,"start":873,"enrollment":874,"conditions":875,"interventions":877},"NCT01648946","Transfusion Requirements in Critically Ill Oncologic Patient",[87],"2013-06","2012-06",300,[876],"Anemia",[858,858],{"trials":879,"activeCount":96},[],{"trials":881,"activeCount":96},[],{"intervention":883,"totalTrials":199,"cells":884},"5-FU, Capecitabine, Oxaliplatin, Leucovorin.",{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":891,"PHASE4":903,"NA":905},{"trials":886,"activeCount":96},[],{"trials":888,"activeCount":96},[],{"trials":890,"activeCount":96},[],{"trials":892,"activeCount":96},[893],{"nctId":894,"briefTitle":895,"status":190,"phases":896,"primaryCompletion":897,"completion":898,"start":899,"enrollment":900,"conditions":901,"interventions":902},"NCT01941979","A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment.",[87],"2015-09","2016-09","2011-09",309,[23],[883],{"trials":904,"activeCount":96},[],{"trials":906,"activeCount":96},[],{"intervention":908,"totalTrials":92,"cells":909},"Metformin",{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":934,"PHASE4":936,"NA":938},{"trials":911,"activeCount":96},[],{"trials":913,"activeCount":96},[],{"trials":915,"activeCount":96},[916,926],{"nctId":917,"briefTitle":918,"status":405,"phases":919,"primaryCompletion":873,"start":920,"enrollment":921,"conditions":922,"interventions":924},"NCT01971034","Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.",[86],"2011-06",41,[923],"Pancreatic Adenocarcinoma Advanced or Metastatic",[925,908],"Paclitaxel",{"nctId":927,"briefTitle":928,"status":190,"phases":929,"primaryCompletion":930,"start":778,"enrollment":720,"conditions":931,"interventions":933},"NCT02279758","A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors",[86],"2017-12",[932],"Well-differentiated Neuroendocrine Tumors",[908],{"trials":935,"activeCount":96},[],{"trials":937,"activeCount":96},[],{"trials":939,"activeCount":96},[],{"intervention":925,"totalTrials":199,"cells":941},{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":943,"activeCount":96},[],{"trials":945,"activeCount":96},[],{"trials":947,"activeCount":96},[948],{"nctId":917,"briefTitle":918,"status":405,"phases":949,"primaryCompletion":873,"start":920,"enrollment":921,"conditions":950,"interventions":951},[86],[923],[925,908],{"trials":953,"activeCount":96},[],{"trials":955,"activeCount":96},[],{"trials":957,"activeCount":96},[],{"intervention":959,"totalTrials":199,"cells":960},"Droperidol",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":962,"activeCount":96},[],{"trials":964,"activeCount":96},[],{"trials":966,"activeCount":96},[967],{"nctId":968,"briefTitle":969,"status":405,"phases":970,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":975,"interventions":977},"NCT04411069","Simplified Algorithm for the Prevention of Postoperative Nausea and Vomiting in an Oncological Hospital",[86],"2020-03-20","2021-03-20","2019-02-20",270,[28,976],"Postoperative Vomiting",[959],{"trials":979,"activeCount":96},[],{"trials":981,"activeCount":96},[],{"trials":983,"activeCount":96},[],{"intervention":413,"totalTrials":199,"cells":985},{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":996,"PHASE4":998,"NA":1000},{"trials":987,"activeCount":96},[],{"trials":989,"activeCount":96},[],{"trials":991,"activeCount":96},[992],{"nctId":403,"briefTitle":404,"status":405,"phases":993,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":994,"interventions":995},[86],[18],[413,72,414,415],{"trials":997,"activeCount":96},[],{"trials":999,"activeCount":96},[],{"trials":1001,"activeCount":96},[],{"intervention":414,"totalTrials":199,"cells":1003},{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1014,"PHASE4":1016,"NA":1018},{"trials":1005,"activeCount":96},[],{"trials":1007,"activeCount":96},[],{"trials":1009,"activeCount":96},[1010],{"nctId":403,"briefTitle":404,"status":405,"phases":1011,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":1012,"interventions":1013},[86],[18],[413,72,414,415],{"trials":1015,"activeCount":96},[],{"trials":1017,"activeCount":96},[],{"trials":1019,"activeCount":96},[],{"intervention":415,"totalTrials":199,"cells":1021},{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1032,"PHASE4":1034,"NA":1036},{"trials":1023,"activeCount":96},[],{"trials":1025,"activeCount":96},[],{"trials":1027,"activeCount":96},[1028],{"nctId":403,"briefTitle":404,"status":405,"phases":1029,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":1030,"interventions":1031},[86],[18],[413,72,414,415],{"trials":1033,"activeCount":96},[],{"trials":1035,"activeCount":96},[],{"trials":1037,"activeCount":96},[],{"intervention":1039,"totalTrials":199,"cells":1040},"Paclitaxel\u002Fdoxorubicin\u002Fcyclophosphamide",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1059,"PHASE4":1061,"NA":1063},{"trials":1042,"activeCount":96},[],{"trials":1044,"activeCount":96},[],{"trials":1046,"activeCount":96},[1047],{"nctId":1048,"briefTitle":1049,"status":1050,"phases":1051,"primaryCompletion":1052,"completion":1053,"start":1054,"enrollment":1055,"conditions":1056,"interventions":1058},"NCT01329627","Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer","TERMINATED",[86],"2011-08","2012-08","2010-08",12,[1057],"Locally Advanced HER2-negative Breast Cancer",[1039,1039],{"trials":1060,"activeCount":96},[],{"trials":1062,"activeCount":96},[],{"trials":1064,"activeCount":96},[],{"intervention":1066,"totalTrials":199,"cells":1067},"mFOLFIRINOX",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1069,"activeCount":96},[],{"trials":1071,"activeCount":96},[],{"trials":1073,"activeCount":96},[1074],{"nctId":1075,"briefTitle":1076,"status":190,"phases":1077,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1084},"NCT05354817","Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin",[86],"2022-12","2023-12","2021-10-22",25,[1083],"Colorectal Cancer Stage IV",[1066],{"trials":1086,"activeCount":96},[],{"trials":1088,"activeCount":96},[],{"trials":1090,"activeCount":96},[],{"intervention":1092,"totalTrials":199,"cells":1093},"Ivermectin",{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1095,"activeCount":96},[],{"trials":1097,"activeCount":96},[],{"trials":1099,"activeCount":96},[1100],{"nctId":1101,"briefTitle":1102,"status":1050,"phases":1103,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1110},"NCT04447235","Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection",[86],"2022-06-30","2020-07-23",77,[30,1108,1109],"COVID","Coronavirus Infection",[1092,1111],"Losartan",{"trials":1113,"activeCount":96},[],{"trials":1115,"activeCount":96},[],{"trials":1117,"activeCount":96},[],{"intervention":1111,"totalTrials":199,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1130,"PHASE4":1132,"NA":1134},{"trials":1121,"activeCount":96},[],{"trials":1123,"activeCount":96},[],{"trials":1125,"activeCount":96},[1126],{"nctId":1101,"briefTitle":1102,"status":1050,"phases":1127,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1128,"interventions":1129},[86],[30,1108,1109],[1092,1111],{"trials":1131,"activeCount":96},[],{"trials":1133,"activeCount":96},[],{"trials":1135,"activeCount":96},[],{"intervention":1137,"totalTrials":199,"cells":1138},"Intraperitoneal chemotherapy",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1155,"PHASE4":1157,"NA":1159},{"trials":1140,"activeCount":96},[],{"trials":1142,"activeCount":96},[],{"trials":1144,"activeCount":96},[1145],{"nctId":1146,"briefTitle":1147,"status":190,"phases":1148,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":720,"conditions":1152,"interventions":1154},"NCT05541146","Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis",[86],"2024-07","2025-01","2022-06-01",[21,1153],"Peritoneal Carcinomatosis",[1137],{"trials":1156,"activeCount":96},[],{"trials":1158,"activeCount":96},[],{"trials":1160,"activeCount":96},[],{"intervention":1162,"totalTrials":199,"cells":1163},"Hu3S193",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1180,"PHASE4":1182,"NA":1184},{"trials":1165,"activeCount":96},[],{"trials":1167,"activeCount":96},[],{"trials":1169,"activeCount":96},[1170],{"nctId":1171,"briefTitle":1172,"status":1050,"phases":1173,"primaryCompletion":1174,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1179},"NCT01370239","HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy",[86],"2015-10","2018-05-25","2013-11",23,[15],[1162],{"trials":1181,"activeCount":96},[],{"trials":1183,"activeCount":96},[],{"trials":1185,"activeCount":96},[],{"intervention":1187,"totalTrials":199,"cells":1188},"mFLOX",{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1206,"PHASE4":1208,"NA":1210},{"trials":1190,"activeCount":96},[],{"trials":1192,"activeCount":96},[],{"trials":1194,"activeCount":96},[1195],{"nctId":1196,"briefTitle":1197,"status":190,"phases":1198,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1205},"NCT02896803","Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer",[86],"2021-07","2021-12","2016-08",37,[1204],"Pancreatic Neoplasms",[1187],{"trials":1207,"activeCount":96},[],{"trials":1209,"activeCount":96},[],{"trials":1211,"activeCount":96},[],{"intervention":1213,"totalTrials":199,"cells":1214},"Sunitinib",{"EARLY_PHASE1":1215,"PHASE1":1217,"PHASE2":1219,"PHASE3":1232,"PHASE4":1234,"NA":1236},{"trials":1216,"activeCount":96},[],{"trials":1218,"activeCount":96},[],{"trials":1220,"activeCount":96},[1221],{"nctId":1222,"briefTitle":1223,"status":190,"phases":1224,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1231},"NCT03592199","Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib",[86],"2019-12-11","2022-12-11","2017-12-11",7,[1230],"Clear Cell Renal Cell Carcinoma",[1213],{"trials":1233,"activeCount":96},[],{"trials":1235,"activeCount":96},[],{"trials":1237,"activeCount":96},[],{"intervention":1239,"totalTrials":199,"cells":1240},"Metformin and Fluorouracil",{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1242,"activeCount":96},[],{"trials":1244,"activeCount":96},[],{"trials":1246,"activeCount":96},[1247],{"nctId":1248,"briefTitle":1249,"status":405,"phases":1250,"primaryCompletion":1251,"completion":1252,"start":780,"enrollment":323,"conditions":1253,"interventions":1255},"NCT01941953","Metformin and 5-fluorouracil for Refractory Colorectal Cancer.",[86],"2014-11","2015-03",[1254],"Metastatic Colorectal Cancer",[1239],{"trials":1257,"activeCount":96},[],{"trials":1259,"activeCount":96},[],{"trials":1261,"activeCount":96},[],{"intervention":1263,"totalTrials":199,"cells":1264},"Docetaxel",{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1282,"PHASE4":1284,"NA":1286},{"trials":1266,"activeCount":96},[],{"trials":1268,"activeCount":96},[],{"trials":1270,"activeCount":96},[1271],{"nctId":1272,"briefTitle":1273,"status":190,"phases":1274,"primaryCompletion":1275,"completion":1276,"start":1277,"enrollment":720,"conditions":1278,"interventions":1280},"NCT03700099","Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide",[86],"2024-03-01","2025-04-01","2019-09-03",[18,1279],"Castration-resistant Prostate Cancer",[1263,1281],"Enzalutamide",{"trials":1283,"activeCount":96},[],{"trials":1285,"activeCount":96},[],{"trials":1287,"activeCount":96},[],{"intervention":1281,"totalTrials":199,"cells":1289},{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1294,"PHASE3":1300,"PHASE4":1302,"NA":1304},{"trials":1291,"activeCount":96},[],{"trials":1293,"activeCount":96},[],{"trials":1295,"activeCount":96},[1296],{"nctId":1272,"briefTitle":1273,"status":190,"phases":1297,"primaryCompletion":1275,"completion":1276,"start":1277,"enrollment":720,"conditions":1298,"interventions":1299},[86],[18,1279],[1263,1281],{"trials":1301,"activeCount":96},[],{"trials":1303,"activeCount":96},[],{"trials":1305,"activeCount":96},[],{"intervention":1307,"totalTrials":199,"cells":1308},"Cisplatin",{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1326,"PHASE4":1328,"NA":1330},{"trials":1310,"activeCount":96},[],{"trials":1312,"activeCount":96},[],{"trials":1314,"activeCount":96},[1315],{"nctId":1316,"briefTitle":1317,"status":190,"phases":1318,"primaryCompletion":1319,"completion":1319,"start":873,"enrollment":1320,"conditions":1321,"interventions":1323},"NCT01973101","Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.",[86],"2017-04",120,[1322],"Patients Diagnosed With Advanced Carcinoma of Uterine Cervix t",[1307,1324,1325],"Gemcitabine","cisplatin",{"trials":1327,"activeCount":96},[],{"trials":1329,"activeCount":96},[],{"trials":1331,"activeCount":96},[],{"intervention":1324,"totalTrials":199,"cells":1333},{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1335,"activeCount":96},[],{"trials":1337,"activeCount":96},[],{"trials":1339,"activeCount":96},[1340],{"nctId":1316,"briefTitle":1317,"status":190,"phases":1341,"primaryCompletion":1319,"completion":1319,"start":873,"enrollment":1320,"conditions":1342,"interventions":1343},[86],[1322],[1307,1324,1325],{"trials":1345,"activeCount":96},[],{"trials":1347,"activeCount":96},[],{"trials":1349,"activeCount":96},[],{"intervention":1351,"totalTrials":199,"cells":1352},"Capecitabine",{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1357,"PHASE3":1369,"PHASE4":1371,"NA":1373},{"trials":1354,"activeCount":96},[],{"trials":1356,"activeCount":96},[],{"trials":1358,"activeCount":96},[1359],{"nctId":1360,"briefTitle":1361,"status":405,"phases":1362,"primaryCompletion":1176,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1367},"NCT01941966","A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.",[86],"2010-11",51,[1366],"Anal Canal Cancer.",[1351,1368],"Mitomycins",{"trials":1370,"activeCount":96},[],{"trials":1372,"activeCount":96},[],{"trials":1374,"activeCount":96},[],{"intervention":1368,"totalTrials":199,"cells":1376},{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1387,"PHASE4":1389,"NA":1391},{"trials":1378,"activeCount":96},[],{"trials":1380,"activeCount":96},[],{"trials":1382,"activeCount":96},[1383],{"nctId":1360,"briefTitle":1361,"status":405,"phases":1384,"primaryCompletion":1176,"start":1363,"enrollment":1364,"conditions":1385,"interventions":1386},[86],[1366],[1351,1368],{"trials":1388,"activeCount":96},[],{"trials":1390,"activeCount":96},[],{"trials":1392,"activeCount":96},[],{"intervention":1394,"totalTrials":199,"cells":1395},"ferric hydroxide saccharate",{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1397,"activeCount":96},[],{"trials":1399,"activeCount":96},[],{"trials":1401,"activeCount":96},[1402],{"nctId":1403,"briefTitle":1404,"status":190,"phases":1405,"primaryCompletion":1406,"completion":1406,"start":1407,"enrollment":850,"conditions":1408,"interventions":1409},"NCT01168505","Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients",[86],"2014-12","2010-05",[15],[1394],{"trials":1411,"activeCount":96},[],{"trials":1413,"activeCount":96},[],{"trials":1415,"activeCount":96},[],{"intervention":1417,"totalTrials":199,"cells":1418},"Valproic Acid",{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1435,"PHASE4":1437,"NA":1439},{"trials":1420,"activeCount":96},[],{"trials":1422,"activeCount":96},[],{"trials":1424,"activeCount":96},[1425],{"nctId":1426,"briefTitle":1427,"status":405,"phases":1428,"primaryCompletion":1251,"completion":1251,"start":1429,"enrollment":1430,"conditions":1431,"interventions":1434},"NCT01695122","Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma",[86],"2012-09",14,[25,1432,1433],"Oral Cavity Cancer","Oropharyngeal Cancer",[1417],{"trials":1436,"activeCount":96},[],{"trials":1438,"activeCount":96},[],{"trials":1440,"activeCount":96},[],{"intervention":1442,"totalTrials":199,"cells":1443},"opioid-free group",{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1450,"PHASE4":1452,"NA":1454},{"trials":1445,"activeCount":96},[],{"trials":1447,"activeCount":96},[],{"trials":1449,"activeCount":96},[],{"trials":1451,"activeCount":96},[],{"trials":1453,"activeCount":96},[],{"trials":1455,"activeCount":96},[1456],{"nctId":1457,"briefTitle":1458,"status":190,"phases":1459,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1463,"conditions":1464,"interventions":1465},"NCT03212456","Evaluation of Post-operative Biochemical Recurrence in Patients Submitted to Radical Prostatectomy Under General Opioid-free Anesthesia Compared to Conventional General Anesthesia",[89],"2020-09-30","2020-12-30","2017-01-12",146,[18],[1442,1466],"Opioid Group",{"intervention":1466,"totalTrials":199,"cells":1468},{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1473,"PHASE3":1475,"PHASE4":1477,"NA":1479},{"trials":1470,"activeCount":96},[],{"trials":1472,"activeCount":96},[],{"trials":1474,"activeCount":96},[],{"trials":1476,"activeCount":96},[],{"trials":1478,"activeCount":96},[],{"trials":1480,"activeCount":96},[1481],{"nctId":1457,"briefTitle":1458,"status":190,"phases":1482,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1463,"conditions":1483,"interventions":1484},[89],[18],[1442,1466],{"intervention":1486,"totalTrials":199,"cells":1487},"Drug omission",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1489,"activeCount":96},[],{"trials":1491,"activeCount":96},[],{"trials":1493,"activeCount":96},[],{"trials":1495,"activeCount":96},[],{"trials":1497,"activeCount":96},[],{"trials":1499,"activeCount":96},[1500],{"nctId":1501,"briefTitle":1502,"status":405,"phases":1503,"primaryCompletion":1504,"completion":1504,"start":1505,"enrollment":1506,"conditions":1507,"interventions":1508},"NCT04350229","Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer",[89],"2022-06-20","2020-03-27",86,[15],[1486],{"intervention":1510,"totalTrials":199,"cells":1511},"Trastuzumab",{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1516,"PHASE3":1518,"PHASE4":1520,"NA":1522},{"trials":1513,"activeCount":96},[],{"trials":1515,"activeCount":96},[],{"trials":1517,"activeCount":96},[],{"trials":1519,"activeCount":96},[],{"trials":1521,"activeCount":96},[],{"trials":1523,"activeCount":96},[1524],{"nctId":1525,"briefTitle":1526,"status":1527,"phases":1528,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":96,"conditions":1532,"interventions":1534},"NCT02102438","Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer","WITHDRAWN",[89],"2016-04","2018-04","2014-04",[15,1533],"HER-2 Positive Breast Cancer",[1510,1535,1536],"Weekly Paclitaxel","Carboplatin",{"intervention":1535,"totalTrials":199,"cells":1538},{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1545,"PHASE4":1547,"NA":1549},{"trials":1540,"activeCount":96},[],{"trials":1542,"activeCount":96},[],{"trials":1544,"activeCount":96},[],{"trials":1546,"activeCount":96},[],{"trials":1548,"activeCount":96},[],{"trials":1550,"activeCount":96},[1551],{"nctId":1525,"briefTitle":1526,"status":1527,"phases":1552,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":96,"conditions":1553,"interventions":1554},[89],[15,1533],[1510,1535,1536],{"intervention":1536,"totalTrials":199,"cells":1556},{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1561,"PHASE3":1563,"PHASE4":1565,"NA":1567},{"trials":1558,"activeCount":96},[],{"trials":1560,"activeCount":96},[],{"trials":1562,"activeCount":96},[],{"trials":1564,"activeCount":96},[],{"trials":1566,"activeCount":96},[],{"trials":1568,"activeCount":96},[1569],{"nctId":1525,"briefTitle":1526,"status":1527,"phases":1570,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":96,"conditions":1571,"interventions":1572},[89],[15,1533],[1510,1535,1536]]